Related Experiment Video
Updated: Sep 4, 2026
A Rat Model of Pouchitis Following Proctocolectomy and Ileal Pouch-Anal Anastomosis Using Dextran Sulfate Sodium
Published on: May 31, 2024
The Proctitis Paradox: Refractory Ulcerative Proctitis Associated With Development of Disease Complications in a
Sreecanth S Raja1,2, Samuel P Costello1,2, Alexandra Sadler2,3
1Faculty of Health and Medical Sciences University of Adelaide Adelaide South Australia Australia.
Background:
Despite limited extent, patients with ulcerative proctitis (UP) can suffer from debilitating symptoms, complications, and risk of disease extension. The aim was to provide a contemporary real-world insight into the management and outcomes of UP.
Methods:
A retrospective cohort study was conducted of UP patients attending three tertiary hospitals in Adelaide, South Australia, between 2015 and 2024. Demographic, treatment, and disease-related data were captured. Treatment success was defined as clinical response at last follow up. The primary outcome was the development of disease-related complications.
Results:
Of 185 patients with UP, 60.5% were female, mean age at diagnosis was 41.1 years (±14.2) and median duration of follow up was 4.18 years (IQR 2.0-7.3 years). Most patients (n = 114, 62.3%) achieved treatment success with 5-ASA therapy, but one third (n = 56, 30.3%) developed refractory UP. For those with refractory UP, treatment success was achieved in 45% of patients using systemic immunomodulators (n = 40) and in 59% using advanced therapies (n = 27). Topical tacrolimus was used in 10 patients, of whom three achieved treatment success. Overall, 34 patients (18.4%) developed either proximal disease extension (n = 22, 11.9%) or traditional UC related complications including hospitalization (n = 15, 8.1%) and colectomy (n = 1, 0.05%). The presence of refractory UP was associated with development of traditional UC related complications (p < 0.0001).
Conclusion:
Despite a short segment of inflammation, UP remains a clinical conundrum as many patients develop refractory disease, disease extension, and complications. Further prospective studies are required to define optimal therapeutic strategies for this under-recognized cohort.
Related Concept Videos
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
01:26Inflammatory Bowel Disease I: Introduction
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations